Nuvalent Inc. (NASDAQ: NUVL) presented new clinical and preclinical data for its investigational cancer drug zidesamtinib at the American Association ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE